BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Synta Raises $52M in Offering to Fund Ganetespib’s Phase III
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Synta Raises $52M in Offering to Fund Ganetespib’s Phase III
Nov. 14, 2013
By
Randy Osborne
No Comments
Synta Pharmaceuticals Corp.’s new money from a public offering – about $52.5 million in gross proceeds – will fuel an expanded Phase III push with the heat-shock protein 90 inhibitor ganetespib in non-small-cell lung cancer (NSCLC).
BioWorld